Celgene has announced a new arm of a phase 1b study that will study Novocure’s noninvasive brain cancer therapy alongside a pair of cancer drugs.

Sarepta CEO Doug Ingram aims to raise $250 million in a public stock offering as the company looks beyond its first product, DMD therapy Exondys 51.

The outlay gives Lilly the rights to a drug designed to treat autoimmune diseases by boosting the number and activity of regulatory T cells.

The drug failed to improve progression-free survival in mesothelioma, causing the stocks of Bayer’s collaborators ImmunoGen and MorphoSys to slip.

Check out Friday's dose of biotech's news of note.

Feinstein Institute-led researchers used an Alzheimer’s drug to reduce inflammation in people with metabolic syndrome.

Staffers are set to move to their new digs in east London in the middle of next year, shortly the EMA is scheduled to leave a neighboring building.

Ex-Novo exec Høiland became Radius' CEO, ex-Sanofi Genzyme CEO Meeker joined Trevi as chairman, Myovant tapped four execs with Big Pharma experience.

The positive narrative spun by Ironwood’s management failed to convince investors, who seized on perceived underwhelming efficacy data.